EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Feasibility of clinical implementation and acceptability of patient-reported screening for chemotherapy-induced peripheral neuropathy (CIPN)

Alice Treloar, Peter Grimison, Victoria Choi, Jed Young, Katelin Mayer, Tiffany Li, Frances Boyle, Tracy King, David Mizrahi, Lisa G Horvath, David Goldstein, Susanna B Park

Supportive Care in Cancer · 2026-11 · 34 (11)

DOI: 10.1007/s00520-026-11296-4 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Supportive Care in Cancer, online erschienen am 08.10.2026. Verfasst von Alice Treloar und 11 weiteren Autor:innen. Beteiligte Einrichtung: Brain and Mind Centre, The University of Sydney, Sydney, NSW, Australia. Hauptthemen laut MEDLINE: Peripheral Nervous System Diseases, Antineoplastic Agents, Mass Screening. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Chemotherapy-induced peripheral neuropathy (CIPN) is a major side-effect of cancer treatment, leading to early treatment cessation and long-lasting disability. This project aimed to determine acceptability and barriers of routine CIPN screening.

Methods

In a prospective sample across two sites, patients scheduled for treatment or treated with neurotoxic therapy were eligible to complete CIPN screening at any cycle. Three brief patient-reported outcome screening tools (NCI-PRO-CTCAE, PNQ, and EviQ) and a short feasibility questionnaire were deployed (termed CIPN-Screen) during appointments (Centre 1) or via automated text messages (Centre 2).

Results

Seven hundred fifty-five screens were undertaken in 159 participants between March 2022 and November 2023, with 109 at Centre 1 (median[IQR] 1[1]screen) and 646 at Centre 2 (median[IQR] 8[6]screens). Automatic text message reminders at Centre 2 enabled longitudinal assessments to be collected. 426 screens (56.4%) identified CIPN symptoms with 138 (18.3%) moderate-to-severe. Most respondents reported that the CIPN-Screen was easy to complete (92.0%, n = 671), easy to understand (91.6%, n = 668), and helpful to describe symptoms (85.6%, n = 624). Acceptability did not differ by age, sex, or chemotherapy type; however, acceptability did differ according to CIPN symptom severity ( P = 0.0002). There were significant differences in CIPN symptom score over time ( P < 0.0001, n = 52), indicating that the CIPN-Screen detected symptom evolution over time.

Conclusion

Questionnaire-based CIPN screening is feasible and assists in symptom profiling for patients treated with neurotoxic chemotherapy. Implications for cancer survivors CIPN is an important toxicity with lasting effects for cancer survivors. Identifying better approaches to patient-relevant CIPN screening will enable improved care for cancer survivors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Peripheral Nervous System DiseasesAntineoplastic AgentsMass ScreeningHumansFemaleFeasibility StudiesProspective StudiesMaleMiddle AgedAgedPatient Reported Outcome MeasuresNeoplasmsSurveys and QuestionnairesAdult

Stichwörter der Autor:innen

CIPNCancerChemotherapy induced peripheral neuropathyQuality of lifeScreening

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Brain and Mind Centre, The University of Sydney, Sydney, NSW, Australia.
  • Chris O'Brien Lifehouse, Sydney, NSW, Australia.
  • Sydney Medical School, The University of Sydney, Sydney, NSW, Australia.
  • Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
  • Prince of Wales Hospital, Sydney, NSW, Australia.
  • School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.

Zitieren

APA

Treloar, A., Grimison, P., Choi, V., Young, J., Mayer, K., Li, T., Boyle, F., King, T., Mizrahi, D., Horvath, L. G., Goldstein, D., & Park, S. B. (2026). Feasibility of clinical implementation and acceptability of patient-reported screening for chemotherapy-induced peripheral neuropathy (CIPN). Supportive Care in Cancer, 34(11). https://doi.org/10.1007/s00520-026-11296-4

Vancouver

Treloar A, Grimison P, Choi V, Young J, Mayer K, Li T, et al. Feasibility of clinical implementation and acceptability of patient-reported screening for chemotherapy-induced peripheral neuropathy (CIPN). Supportive Care in Cancer. 2026;34(11). doi:10.1007/s00520-026-11296-4

BibTeX
@article{Treloar2026,
  author = {Treloar, Alice and Grimison, Peter and Choi, Victoria and Young, Jed and Mayer, Katelin and Li, Tiffany and Boyle, Frances and King, Tracy and Mizrahi, David and Horvath, Lisa G and Goldstein, David and Park, Susanna B},
  title = {Feasibility of clinical implementation and acceptability of patient-reported screening for chemotherapy-induced peripheral neuropathy (CIPN)},
  journal = {Supportive Care in Cancer},
  year = {2026},
  volume = {34},
  number = {11},
  doi = {10.1007/s00520-026-11296-4}
}
Kostenlos starten →